Depression Screening Market Research Report - Forecast till 2030

Depression Screening Market: Information by Disease Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders and Eating Disorders), Diagnosis (Psychological Test, Lab Tests and Depression Screening Tests) Treatment (Medication, Brain-Stimulation Treatments and Substance Abuse Treatment), End User and Region - Forecast till 2030

ID: MRFR/Pharma/2518-CR | July 2019 | Region: Global | 102 pages

Depression Screening Mental Health Market Speak to Analyst Request a Free Sample

Depression Screening Market Overview


The increasing problem of mental disorders all over the world and owing to the increase in the use of digital health technologies for mental health acts as s driving force for the growth of the depression screening market. The changing lifestyle and living standards and the growing use of smoking and the increase in the consumption of alcohol are the main factors that lead to the problem of mental disorder and hence leads to depression. Because of the growing population, and lack of medical experts the depression screening market is touching heights in terms of growth.


Depression is a common disease and it should not be mixed with regular sadness. It is a very dangerous disease as it affects the behaviour of a person. Hence depression test is required and in the technology-driven era, depression screening is done using advanced technology. The depression screening market is expected to grow at a high CAGR of 5.96% to reach USD 7836.67 million during the forecast period.


COVID 19 Analysis


The global pandemic of COVID 19 has not only affected the physical well-being of individuals, but it affected the psychological aspects also. Prolonged physical distance associated with social isolation, collective grief, the virus itself are some of the major side effects of COVID 19 which everyone has to face and it has put a negative impact on the minds of the people. Because of COVID 19, unemployment has also increased many times which not only affects the financial position but also affects emotionally. These are the few reasons which lead to mental disorders and hence depression.


Owing to the increase in the number of patients, it became necessary for the adoption of an online depression screening test. those who do not feel comfortable visiting doctors can use it from their place only and hence it is expected that the depression screening market will grow in the global market at the beginning of the second quarter of the coming year.


Market Dynamics


Drivers


Owing the increase in the cases of mental disorders and the rise in the adoption of new therapies and treatments using advanced technology are the common factors that drive the growth of the depression screening market. Also, the World Health Organization has called depression the leading cause of disability across the globe it also drives the growth-share.


Opportunities


The increasing awareness among the people regarding the health issues and its timely screening have boosted the growth of the market. Also, the advancement in technology and its integration with the healthcare sector have helped in the growth of the global market. Because of the frequent suicide cases owing to the global pandemic many governments have taken initiatives regarding regular screening of depression or anxiety tests which is also a big opportunity for the depression screening market.


Restraints


Although technology is booming in every sector possible still there is lack of awareness of mental disorders and treatments in most of the developing nations hinders the growth of the depression screening market.


Value Chain Analysis


Just like due importance is given to high blood pressure, diabetes, and various other physical disorders, the mental disorder should also be given due importance. That is why the depression screening market is growing at a high rate and screening is just the first step in getting help. Depression is not only a mental sickness but is an issue of major concern as it leads to suicidal tendencies.


With the depression screening market, now one can take free screening so that those who are in doubt regarding the symptoms of depression can get properly evaluated and can get treatment at an early stage.


Market Segmentation


The depression screening market has been divided based on division type, diagnosis, treatment, end-users, and region.


Based on disease type


The depression screening market is divided based on disease type into mood disorders, depression, bipolar disorders, anxiety, psychotic disorders, and eating disorders.


Based on diagnosis


The depression screening market is divided based on diagnosis into psychological tests, lab tests, and depression screening tests.


Based on treatment


The depression screening market is divided based on treatment into medication, brain-stimulation treatments, and substance abuse treatment.


Based on end-users


The depression screening market is divided based on end-users into hospitals and clinics, medical research centers, and academic institutes.


Based on region


The depression screening market is divided based on region into America, Europe, Asia-Pacific, and the Middle East, and Africa.


Regional Analysis


In the depression screening market, America holds the largest share. Out of which, owing to the availability of advanced diagnostic and treatment methods, an increasing number of patients, and raising funds for research, the North American region dominates the market.


The second-largest market share in the global depression screening method is held by Europe because of the development of healthcare facilities in many countries like Germany, France, and the U.K.


Owing to the fastest-growing region in the global market, Asia-Pacific holds the third position in the global market. Increasing development in countries like India, South Korea, and China in healthcare facilities has increased the demand for the depression screening market.


Competitive Landscape


The major key players in the depression screening market are as follows:



  • ALLERGAN (Republic of Ireland)

  • Alkermes (Republic of Ireland)

  • AstraZeneca (U.K.)

  • Eli Lily and Company (U.S.)

  • Pfizer Inc. (U.S.)

  • Bristol-Myers Squibb Company (U.S.)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Johnson and Johnson Services, Inc. (U.S.)


Most of the major key players in the depression screening market in the global market operate using the key strategies of product development, innovation, and acquisitions, and mergers.


Recent Developments



  • In November 2018, a campaign for expanding treatment and screening of depression using technology. This campaign has helped in guiding symptoms of depression and how patients can openly discuss their problems with their doctors for better treatment.

  • In October 2017, a new postpartum depression screening program has been launched under which the new mothers have been monitored after 2 days of giving birth and in that, they have to answer few questions by which the doctor will analyze the symptoms of depression. This program is launched by Cedars-Sinai Medical Centre.

  • In November 2020, Janssen announced its merger with Koa Health, and together they will provide cost-effective digital treatment for depression suffering patients and various therapies to strengthen their position in the global market.

  • In recent times many self-management applications have been developed as a result, it helps in managing stress, anxiety and can have a track of their heart rate, blood pressure, and many other things.

  • Many applications related to improvement in thinking skills have also developed to reduce stress and anxiety from the students. These applications help in monitoring serious mental illness. Not only these many skill-training applications have also developed in the recent past to provide social support.


Report Overview


This depression screening market research report consists of the following:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This report contains various aspects related to the depression screening market along with future estimation, the impact of COVID 19 in increasing depression cases, and opportunities and challenges that the market face.


Research Methodology


Data collection is done using large sample size and various statistical models are used to analyze the market data along with key trend analysis. DBMR research methodology is used in data triangulation that has an analysis of the impact of data variables in the market, data mining, and primary (industry expert) validation. Various primary respondents have been chosen for the sample size like doctors, surgeons, medical players, scientists, promotors, healthcare authorities, insurers, and others.


Users


Pharmaceutical companies, the medical device industry, research, and development organization, academic institutes, diagnostic laboratories, healthcare payers, government institutes, and others.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2020: USD 5177.8 million
  • 2030: 7836.67 million
  •   CAGR   5.96% (2020-2030)
      Base Year   2019
      Forecast Period   2020-2030
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Division type, Diagnosis, Treatment, End-users
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), AstraZeneca (U.K.), Eli Lily and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Johnson and Johnson Services, Inc. (U.S.)
      Key Market Opportunities

  • Increasing awareness among the people regarding the health issues
  • Timely screening
  • Advancement in technology and its integration
  •   Key Market Drivers

  • Increase in the cases of mental disorders
  • Rise in the adoption of new therapies and treatments
  • The leading cause of disability


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Depression screening market projected to grow at approximately 5.96% CAGR during the assessment period (2020-2030).

    The valuation of the depression screening market is estimated to increase to USD 7836.67 MN by the end of 2030.

    Increasing cases of patients with various mental disorders, changing lifestyle, and rising funding for R&D & clinical trials are major tailwinds pushing the growth of the global depression screening market.

    North America holds the largest share in the global depression screening market, followed by Europe and the Asia Pacific, respectively.

    ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), AstraZeneca (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (US), and Otsuka Holdings Co., Ltd. (Japan), are some of the top players operating in the global depression screening market.